You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
Copy file name to clipboardExpand all lines: docs/01-intro.md
+5-3Lines changed: 5 additions & 3 deletions
Display the source diff
Display the rich diff
Original file line number
Diff line number
Diff line change
@@ -3,7 +3,7 @@
3
3
4
4
# Introduction
5
5
6
-
This course was developed in Summer 2023 and updated in Fall 2025. We welcome any feedback at help@pvactools.org or by submission of [GitHub issues](https://github.com/griffithlab/pVACtools_Intro_Course/issues).
6
+
This course was developed in Summer 2023 and last updated in Summer 2026. We welcome any feedback at help@pvactools.org or by submission of [GitHub issues](https://github.com/griffithlab/pVACtools_Intro_Course/issues).
7
7
8
8
## Motivation
9
9
@@ -21,7 +21,7 @@ of the aforementioned steps are executed via a modular workflow consisting of to
21
21
prioritization, and selection using a graphical Web-based interface (pVACview), and design of DNA vector–based vaccines (pVACvector) and synthetic long peptide
22
22
vaccines. pVACtools is available at [http://www.pvactools.org](http://www.pvactools.org).
23
23
24
-
<imgsrc="01-intro_files/figure-html//1uz39zaObDGKhEVCGzO0JO35CTbC0oRAM0mxgLcMAA9Y_g3a37485c18b_1_0.png"alt="pVACtools is a cancer immunotherapy tools suite"width="100%"style="display: block; margin: auto;" />
24
+
<imgsrc="01-intro_files/figure-html//1uz39zaObDGKhEVCGzO0JO35CTbC0oRAM0mxgLcMAA9Y_g3e342b543ab_0_0.png"alt="pVACtools is a cancer immunotherapy tools suite"width="100%"style="display: block; margin: auto;" />
25
25
26
26
## Background
27
27
@@ -39,7 +39,9 @@ stability and recognition by cytotoxic T cells [@Richters2019].
39
39
pVACtools can be used as the final step in a well-established variant calling pipeline. It leverages existing tools with functionality related to variant annotation
40
40
(Ensembl VEP [@McLaren2016]), identifying neoantigens from specific sources (e.g. fusions via star-fusion [@Haas2019], AGFusion [@Murphy2016], and Arriba [@Uhrig2021]),
metrics (vaxrank [@Rubinsteyn2017]), and reference proteome similarity (BLAST [@Altschul1990]). Each of these tools tackles specific tasks within the broader goal of
44
46
antigen analysis and is utilized by pVACtools to provide an end-to-end integration of novel algorithms and established tools needed to discover, characterize, prioritize,
45
47
and utilize tumor-specific neoantigens in basic research and clinical applications. Combining pVACtools with existing variant calling pipelines provides an end-to-end
0 commit comments